BCM
IBRX icon

Bayesian Capital Management’s ImmunityBio IBRX Stock Holding History

Bayesian Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-82,100
Closed -$519K – 847
2024
Q2 		$519K Buy
+82,100
New +$541K 0.06% 361
2022
Q3 		– Sell
-47,400
Closed -$176K – 848
2022
Q2 		$176K Buy
47,400
+16,100
+51% +$64.7K 0.03% 637
2022
Q1 		$176K Buy
+31,300
New +$192K 0.03% 669

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bayesian Capital Management's IBRX Position: Q3 2024 in Review

Bayesian Capital Management sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 82,100 shares — an estimated $519K sold.

Bayesian Capital Management first reported a position in IBRX in Q1 2022 and held it in 3 quarters. The position peaked at $519K in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Bayesian Capital Management reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 82,100 ImmunityBio shares in Q3 2024, an estimated $519K.
  • Bayesian Capital Management first reported a position in ImmunityBio in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's ImmunityBio position peaked at $519K in Q2 2024.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.